The new WHO classification abolishes the frontier between RAEB-t with 20% of blasts and leukemia with 30% of blasts. We review the definitions of erythroleukemia and discuss the relationship between FAB AML6, RAEB-t and AML6 variant. We ask whether secondary erythroleukemias are the same entity as RAEB-t on survival, karyotype and cytologic characteristics. We suggest that 'AML6 variant' with pure erythroid lineage proliferation would be the real de novo erythroleukemia. Current FAB AML6 entity will probably be classified in either subgroup (1) multilineage dysplasia; (2) therapy-related leukemia; or (3) acute erythroid leukemia subdivided into erythroleukemia (erythroid/myeloid) and pure erythroid leukemia, in the WHO classification -a classification which highlights the importance of clinical and cytogenetic prognostic factors.
Introduction
The subject of malignancies derived from erythroleukemia has been fraught with controversies since its inception. Di Guglielmo reported the original cases in 1917.
1 He described a syndrome composed of an association of immature erythroid and myeloid elements and a disease characterized by a pure normoblastic proliferation.
The 1976 FAB classification defined erythroleukemia upon the overall percentage of myeloblasts. However, owing to the overwhelming erythrocytic component inherent in this disease, a diagnosis of acute erythroleukemia (EL), based on greater than or equal to 30% of the bone marrow elements being myeloblasts could not be established very often. So the 1985 FAB Cooperative Group revised its criteria by requiring at least 30% of the non-erythrocytic elements to be type I or II blasts and defined AML6 as a proliferation of Ͼ50% erythroblasts and Ͼ30% of myeloblasts within non-erythroid cells. 2 
Clinical presentation
The incidence of this disease ranges from 3 to 8%.
3-5 The incidence did not differ in series, including de novo or secondary leukemia. 6 There is a male preponderance. 7 The age distribution appears to be bimodal, with a smaller peak below 20 years and a more definitive and broader peak in the seventh decade of life.
In half of the cases, AML6 are secondary to chemotherapy or immunosuppressive therapy. ELs more commonly complicate treatment with alkylating agents or benzene exposure. AML 6 may also develop as a blastic crisis of myeloprolifer- ative disease or a final evolution of myelodysplastic syndrome.
The most common complaints reported are related to severe anemia. One third of the patients were reported to have hemorrhage. The presence of hepatomegaly or splenomegaly varies between 20 to 40% of the series. 8 Anemia is present in most patients, and is often severe (mean, 7.5 g/dl). Half of the patients have no blasts on the blood smear. Neutrophils and platelets counts are mildly to markedly diminished. Peripheral blood finding may also include a high level of schistocytes and nucleated red cells and pseudo Pelger-Huet neutrophils. But these abnormalities are not specific of erythroleukemia and can evoke other dyserythropoiesis etiologies.
The bone marrow is hypercellular and shows major dysplasia in the red cells. Erythroid lineage is dysplastic, with macroblasts (asynchronous nucleo-cytoplasmic maturation) and basophilic stippling, lack of hemoglobinization and multinucleation. Multilineage dysplasia is present in most of the reports. 8 Megakaryocytes are very often dysplastic, with abnormalities of segmentation of the nucleus or abnormalities of size (micromegakaryoblasts). Dysgranulopoiesis is described in half of the patients. 9 This heterogeneity of trilineage dysplasia can be explained by the fact that erythroleukemia includes primary and secondary diseases.
The 1985 FAB Cooperative Group defines erythroleukemia as a proliferation of Ͼ50% erythroblasts and Ͼ30% of myeloblasts within non-erythroid cells. Some authors described three subtypes of AML6: 7 (1) M6A or Di-Guglielmo's syndrome is characterized by greater or equal to 30% of blasts within non-erythroid cells with less than 30% pronormoblasts. This subgroup is related to the evolution of MDS and presents few karyotype abnormalities. (2) M6B is defined by greater than or equal to 30% pronormoblasts and conversely less than 30% of blasts within nonerythrocytic elements. This group is associated with major karyotype abnormalities and has the highest level of expression of MDR-1 gene product, P-glycoprotein. 10 (3) M6C is characterized by greater or equal to 30% of blasts of non-erythroid cells with greater or equal to 30% pronormoblasts.
This classification of EL according to the number of myeloblasts and pronormoblasts must be difficult to apply since the blasts are very dysplastic. Most importantly this classification is probably underlain by karyotype subgroups.
The new WHO classification abolishes the barrier between RAEB-t and acute leukemia by lowering the number of myeloblasts requested for the definition of acute leukemia to 20%. 11 We confirmed the WHO classification by a retrospective study, which showed that RAEB-t with erythroid component Ͼ50% and below 30% of myeloblasts behave as aggressively as erythroleukemia with the same poor survival of 5 months and with the same dysplastic features and the same cytogenetic abnormalities (Ϫ5/5qϪ; Ϫ7/7qϪ; inv3; 11q abnormalities; 17p abnormalities) as AML6.
Leukemia

Cytochemistry
A large variety of cytochemical stains are available for characterization of erythroid lineage. The periodic acid-Schiff reaction is always negative in normal erythroid differentiation. Aberrant positivity is very often observed in pronormoblasts and basophilic normoblasts in AML6.
The Prussian blue stain demonstrates increased iron stores in AML6 sometimes with ringed sideroblasts. Some authors reported occasional positivity of myeloperoxydase in erythroid cells in EL.
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Immunophenotyping
The most known markers for EL have included glycophorin A and transferrin receptor (CD71). However glycophorin A has been reported to be completely negative in some cases of AML6 probably because it is a late erythroid marker, and CD71 is a non-specific activation marker which can be found in other AML. The platelet CD41 antigen and the myeloid markers as CD13 and CD33 can sometimes be positive. Probably the expression of Rh D antigen or of spectrin in AML6 could have some interest since they are expressed in immature erythroid cells.
14 Markers like beta-sialoglycoprotein, Carbonic anhydrase 1, could be interesting tools to identify minimally differentiated M6. The most important role for antigenic erythroid markers is not in classical AML6, but rather to search for such a primitive erythroid phenotype among the acute undifferentiated leukemia. This entity of minimally differentiated erythroleukemia has been described as AML6 variant 15 and is now called 'pure erythroid leukemia' in the new WHO classification. 16 
Cytogenetics
Although numerous chromosomal abnormalities have been described in AML6, no consistent pattern has been specified. Clonal chromosomal abnormalities are found in 70% to 100% of the patients. This heterogeneity probably reflects inclusions of secondary AML6 and therapy-related AML6 in some series. Loss of all or part of the long arm (q) of chromosomes 5 and/or 7 was observed with no difference in 65% of de novo and secondary AML6. In only one series, the overall frequency of the abnormalities of chromosomes 5 and/or 7 observed in de novo M6 patients is similar to that observed in patients with therapy-related acute myeloid leukemia and substantially higher than that noted in patients with other types of AML de novo. 17 In every series, the incidence of patients with unfavorable karyotype is higher than other types of AML with inv 3;11q23;17 p abnormalities.
The karyotypes are often complex, with multiple abnormalities and subclones. Using FISH, some cases of AML6 clearly demonstrated similar karyotypic abnormalities within both myeloid and erythroid cells. Atkinson et al 17 proposes that a characteristic of this disease may be the presence of an altered primitive cell with features of both the erythroid and myeloid lineages.
Outcome
The outcome is classically poor. In de novo AML6, treatment with intensive chemotherapy with anthracycline and aracytine gives a complete remission (CR) rate of about 62%. 8 In other series, the level of CR does not exceed 10% to 40% especially in secondary AML6. 12 CR, if obtained, may be brief. The median survival is about 23 weeks. The survival is related to karyotypic abnormalities. 8 The allogeneic bone marrow transplantation seems to be the best treatment for patients with abnormalities of 5q or 7q. 18 Even for therapy-related myelodysplasia, transplantation seems to be favorable for long-term disease-free survival.
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Prognosis
The outlook for AML6 patients is quite poor. The response to chemotherapy and the length of survival is dependent on many factors. The most important is karyotype abnormality. 20 The CR in patients with 5q or 7q abnormalities is about 20% and median survival reaches 16 weeks compared to 77 weeks for patients without these abnormalities. 8 The difference of prognosis between de novo and secondary leukemia is related to karyotype abnormalities. The percentage of pronormoblasts seems an important factor of survival according to Kowal-Vern et al, 13 with a mean survival of 34 months in AML6a, 3.5 months in AML6b and 10.5 months for AML6c. However, for other authors, more than the percentage of erythroblasts, cytogenetic abnormalities correlate with the rate of CR. 12, 17, 21, 22 Age is an important factor; older patients have a low CR and a short survival. Expression of P-glycoprotein is clearly a poor factor of survival.
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Conclusion
The new WHO classification subdivides acute erythroid leukemias in erythroleukemia (erythroid/myeloid) and pure erythroid leukemia. Independently of the pure erythroid leukemia, most of the cases appear to be a bilineage leukemia. AML6 will probably be classified into three subgroups: (1) leukemia with multilineage dysplasia; (2) therapy-related AML and myelodysplastic syndromes; (3) acute erythroid leukemia subdivided in eythroleukemia (erythroid/myeloid) and pure erythroid leukemia. This new classification underlines the heterogeneity of AML6. Some authors did not observe any difference on survival, karyotype and cytological characteristics between AML6 and RAEB-t with Ͼ50% of erythroblasts. Therefore more and more current RAEB-t will be classified as AML6.
The percentage of blasts within non-erythroid elements and pronormoblasts determined for a prognosis factor must be confirmed in a large series, since it seems to be correlated with cytogenetic subgroups. Introduction of prognostic factors as multilineage dysplasia and previous history of exposure to mutagenic agents in the WHO classification is necessary for AML6, but other prognostic markers as poor risk karyotype (abnormalities of chromosomes 5 or 7), presence of P-glycoprotein 10 or Flt3 duplication 22 could be useful for therapeutic decisions. Even if 'AML with multilineage dysplasia' or 'therapy-related AML' categories imply that poor risk prognostic factors, such as P-glycoprotein expression or poor-risk cytogenetic abnormalities are likely to be present, the role of these prognostic factors should be specified in independent large studies. Many questions persist. In RAEB, is there a justification to differentiate patients with less than 20% of myeloblasts and more than 50% of erythroid precursors, and patients with less than 50% of erythroid precursors? As AML6 is a clonal disease with at least two lineages involvement, would it not be better renamed AML6, as RAEB with more than 50% of erythroblasts, and consider the AML6 variant as the true erythroleukemia? 23 What is the role of intensive chemotherapy and allogeneic transplantation exactly? All these questions must be answered in a larger series.
